A. Westelinck

发表

Same Drug, Different Dosing: Differences in Dosing for Drugs Approved in the United States, Europe, and Japan

J. Sato, H. Malinowski, A. Westelinck, 2008, Journal of clinical pharmacology.

Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact

Jiri Aubrecht, Weida Tong, Huixiao Hong, 2010, Nature Reviews Drug Discovery.

Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group.

Peggy H. Wong, A. Snapir, S. Khambata-Ford, 2011, Pharmacogenomics.

Postmarketing drug dosage changes of 499 FDA‐approved new molecular entities, 1980–1999

Carl Peck, C. Peck, Howard Lee, 2002, Pharmacoepidemiology and drug safety.

Evolution of Drug Development and its Regulatory Process

H. Malinowski, A. Westelinck, 2004 .

PhRMA Survey of Pharmacogenomic and Pharmacodynamic Evaluations: What Next?

A. Snapir, C. López-Correa, N. Cohen, 2012, Clinical pharmacology and therapeutics.